About ATTERX BIOTHERAPEUTICS
Atterx Biotherapeutics is a specialty pharmaceutical company focused on developing novel solutions to prevent and treat antibiotic-resistant bacterial infections, including C-1205 for catheter-associated urinary tract infections and GN-4474 for gram-negative bacterial infections. The company has received FDA Fast Track Designation for C-1205.
Development of novel products to prevent and treat antibiotic-resistant bacterial infectionsUtilization of bacterial interference technology (C-1205)Utilization of bacterial conjugation technology (GN-4474)Conducting clinical trials (Phase I/II for C-1205, IND filing expected for GN-4474 in 2024)Safety and efficacy demonstrated in laboratory experiments, animal models, and toxicity studies
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to ATTERX BIOTHERAPEUTICS right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.